3.40
3.41%
-0.12
Vivos Therapeutics Inc stock is traded at $3.40, with a volume of 125.91K.
It is down -3.41% in the last 24 hours and up +28.30% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$3.52
Open:
$3.5
24h Volume:
125.91K
Relative Volume:
0.09
Market Cap:
$16.29M
Revenue:
$14.50M
Net Income/Loss:
$-15.41M
P/E Ratio:
-4.7887
EPS:
-0.71
Net Cash Flow:
$-13.04M
1W Performance:
+17.65%
1M Performance:
+28.30%
6M Performance:
+61.90%
1Y Performance:
-19.59%
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
3.40 | 16.29M | 14.50M | -15.41M | -13.04M | -0.71 |
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
Sleep Apnea: Vivos' FDA-Cleared Technology Offers Revolutionary, Non-Invasive Hope for America's Stealth Epidemic - PR Web
Medicare to reimburse for Vivos CARE sleep apnea devices - MSN
Ascendiant Capital Markets Reiterates Buy Rating for Vivos Therapeutics (NASDAQ:VVOS) - Defense World
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call Transcript - Insider Monkey
ARMISTICE CAPITAL, LLC Acquires New Stake in Vivos Therapeutics Inc - GuruFocus.com
Vivos Therapeutics Inc (VVOS) Quarterly 10-Q Report - Quartzy
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones - TipRanks
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3 - Proactive Investors USA
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics Q3 Revenue Jumps 17% as FDA Approves Pediatric OSA Treatment | VVOS Stock News - StockTitan
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call - The Manila Times
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely - Simply Wall St
Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance - MSN
Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes - Proactive Investors Australia
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - Yahoo Finance
Vivos Granted Reimbursement Codes for Oral Appliances for OSA - Sleep Review
Vivos secures new AMA medical codes for OSA devices - Investing.com
Pre-Market Momentum Builds For Vivos Therapeutics (VVOS) Following Key Developments - Stocks Telegraph
Vivos secures new AMA medical codes for OSA devices By Investing.com - Investing.com South Africa
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association - The Manila Times
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment - Proactive Investors UK
Balance Sheet Insights: Vivos Therapeutics Inc (VVOS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Stock Market Recap: Vivos Therapeutics Inc (VVOS) Concludes at 3.08, a -4.35 Surge/Decline - The Dwinnex
Vivos surges on FDA nod for pediatric sleep apnea device - MSN
You might want to take a look at Vivos Therapeutics Inc (VVOS) now - SETE News
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Canada
Vivos Therapeutics announces $4.3 million stock sale - Investing.com
VVOS’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering - MarketWatch
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today - Benzinga
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - StockTitan
Vivos Therapeutics raises $4.3 from institutional investors - Proactive financial news
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Vivos Therapeutics surges on FDA approval for youth sleep apnea treatment device - Mugglehead
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - ForexTV.com
S&P 500 Industrials [Sector] (SRIN) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Metals and Mining Capped Index (TTMN) QuotePress Release - The Globe and Mail
TSX Cannabis Index (XCAN) QuotePress Release - The Globe and Mail
Company’s Banking Shares: Up -92.74% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device - XM
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children - Benzinga
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment - MarketWatch
Vivos Therapeutics’ oral device approved by FDA for pediatric sleep apnea treatment - Proactive Investors UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval - Stocks Telegraph
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):